Catherine J. Wu
YOU?
Author Swipe
View article: CoREST complex inhibition alters RNA splicing to promote neoantigen expression and enhance tumor immunity
CoREST complex inhibition alters RNA splicing to promote neoantigen expression and enhance tumor immunity Open
Epigenetic macromolecular enzyme complexes tightly regulate gene expression at the chromatin level and have recently been found to colocalize with RNA splicing machinery during active transcription; however, the precise functional conseque…
View article: Figure S7 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Figure S7 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma Open
Designed mutations increase the stimulatory strength of D-neopeptides above N-peptides. (A) TILs were stimulated with 5 μM class I-peptides, including N-peptides and D-neopeptides, for 5 days. 5 replicate wells were tested for proliferatio…
View article: Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors Open
Glioblastoma patient characteristics (DFCI)
View article: Supplementary Tables 1, 3, 5-7 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Supplementary Tables 1, 3, 5-7 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma Open
Supplementary Table 1. Somatic mutations of the patient's glioblastoma; Supplementary Table 2. See Excel File; Supplementary Table 3. Literature-derived, glioblastoma-associated TAAs; Supplementary Table 4. See Excel File; Supplementary Ta…
View article: Table S1 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Table S1 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors Open
Primers used in the study.
View article: Table S7 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Table S7 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors Open
Genes enriched in NEAT1-high glioblastoma tumor cells
View article: Figure S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Figure S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma Open
PBMCs collected before vaccination show low/no response to candidate vaccine peptides. (A) The nomenclature of the N-peptides and D-neopeptides. I or II indicate if the peptides were chosen/designed for HLA class I or -II binding; MUT/RNA/…
View article: Figure S8 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Figure S8 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma Open
Vaccinated D-neopeptides activate tumor-infiltrating antitumor T cells. (A) Circos plots provide an overview of the frequencies of Vβ-Jβ pairing in the primary and recurrent tumors. (B) Surface TCR β chain expression of the D-neopeptide-sp…
View article: Table S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Table S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma Open
Predicted TSA/TAA-derived N-peptides and D-neopeptides
View article: Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors Open
Glioblastoma patient characteristics (GSE121810)
View article: Supplementary Fig. 2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Supplementary Fig. 2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors Open
Supplementary Fig. 2 NEAT1 expression is associated with the interferon-gamma response in melanoma.
View article: Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors Open
LncRNA transcriptome analysis in melanoma (GSE78220)
View article: Figure S6 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Figure S6 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma Open
TILs do not respond to N-class I-peptides. TILs were stimulated with 5- or 10 μM N-class I-peptides for 5 days. 5 replicate wells were tested for proliferation, and proliferation was measured by 3H-thymidine incorporation assay. The prolif…
View article: Figure S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Figure S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma Open
Increased T lymphocyte infiltration in the recurrent compared to the primary tumor. (A) CD3 immunohistochemical staining in the primary and recurrent tumor. (B) Three fields of view were selected and counted CD3+ T cells in both perivascul…
View article: Supplementary Fig. 3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Supplementary Fig. 3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors Open
Supplementary Fig. 3 NEAT1 levels are associated with the upregulation of the interferon-gamma pathway in glioblastoma.
View article: Table S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Table S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma Open
Over-/highly expressed genes in the primary glioblastoma when compared with glioblastoma cohort in TCGA Database.
View article: Supplementary Fig. 5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Supplementary Fig. 5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors Open
Supplementary Fig. 5 Classification of single cells.
View article: Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors Open
Melanoma patient characteristics (GSE78220)
View article: Supplementary Fig. 6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Supplementary Fig. 6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors Open
Supplementary Fig. 6 NEAT1 expression in tumor-associated macrophages is associated with TNF-alpha signaling.
View article: Table S8 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Table S8 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors Open
Genes enriched in NEAT1-high macrophages
View article: Supplementary Figures from <i>In Vivo</i> Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
Supplementary Figures from <i>In Vivo</i> Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities Open
Supplementary file contains a PDF version of supplementary figures S1-S7 and associated figure legends.
View article: Supplementary Tables from <i>In Vivo</i> Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
Supplementary Tables from <i>In Vivo</i> Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities Open
Supplementary file contains all supplementary tables S1-S16 in Excel format in the order in which they appear in the text.
View article: Supplementary Fig. S1 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Supplementary Fig. S1 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer Open
Supplementary Fig. S1. Comprehensive analysis of protein expression data in immune and invasive cancer epithelial regions from in various patient cohorts.
View article: Supplementary Tables S2-13 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Supplementary Tables S2-13 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer Open
Supplementary Tables S2-13
View article: Supplementary Fig. S4 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Supplementary Fig. S4 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer Open
Supplementary Fig. S4. Schematic of flow cytometry experiments and differential impact of IFNg stimulation on HR+ breast cancer cells.
View article: Supplementary Fig. S8 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Supplementary Fig. S8 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer Open
Supplementary Fig. S8. Comprehensive analysis of fulvestrant and birinapant treatment in HR+ breast cancer cell.
View article: Supplementary Fig. S7 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Supplementary Fig. S7 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer Open
Supplementary Fig. S7. Impact of treatment with fulvestrant, birinapant, and their combination on a PDX model of HR+ breast cancer.
View article: Unannotated open reading frames expand the antigen repertoire in T cell acute lymphoblastic leukemia
Unannotated open reading frames expand the antigen repertoire in T cell acute lymphoblastic leukemia Open
Background: T cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy in which immature T cells clonally expand and displace normal immune cells in the bone marrow and peripheral blood. Standard chemotherapy ind…
View article: Systematic molecular profiling to identify determinants of response to ibrutinib
Systematic molecular profiling to identify determinants of response to ibrutinib Open
BACKGROUND Whilst the broad clonal architecture of naturally progressing chronic lymphocytic leukemia (CLL) has been described, a comprehensive picture of how chemotherapy and targeted agents reshape that landscape is lacking. Here we inte…
View article: Nodal progression in CLL: Real-world predictors of richter transformation and identification of a distinct high-risk NP-CLL subgroup
Nodal progression in CLL: Real-world predictors of richter transformation and identification of a distinct high-risk NP-CLL subgroup Open
Background Aggressive behavior of chronic lymphocytic leukemia (CLL) is relatively uncommon, but in clinical practice, concern for Richter transformation (RT) often prompts PET-CT and biopsy in patients with progressive lymphadenopathy. Wh…